Roche licenses Rona’s RNAi drug that targets fat cells
Rona Therapeutics grants Roche worldwide rights to an ALK7-silencing candidate, with up to $1.06b in further milestones on the table. Visceral fat is the deep kind, the stuff that wraps around organs in the abdomen, and a small RNA company in Santa Barbara has just handed Roche the rights to a drug
<p>Rona Therapeutics grants Roche worldwide rights to an ALK7-silencing candidate, with up to $1.06b in further milestones on the table. Visceral fat is the deep kind, the stuff that wraps around organs in the abdomen, and a small RNA company in Santa Barbara has just handed Roche the rights to a drug </p>